Preclinical researches revealed that PLX3397 inhibited tumor-associated microglia and enhances sensitivity to chemotherapy of glioma, c-kit-mutated melanoma, prostate cancer, and classical Hodgkin lymphoma (cHL) (93–95). The gene discussed is KIT; the disease is neoplasm.